Showing 1 - 5 results of 5 for search 'John B.A.G. Haanen', query time: 0.01s Refine Results
  1. 1
    Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors

    Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors by Hanna Saadani, Else A. Aalbersberg, Mutamba T. Kayembe, John B.A.G. Haanen, Otto S. Hoekstra, Ronald Boellaard, Marcel P.M. Stokkel

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products

    Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products by Suzanne M. Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, Benoît P. Nicolet, Marleen M. van Loenen, Kim Monkhorst, Alexander A.F.A. Veenhof, Egbert F. Smit, Koen J. Hartemink, John B.A.G. Haanen, Rosa de Groot, Monika C. Wolkers

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma

    Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma by Diane van der Woude, Theo Rispens, Catharina M Korse, Sjoerd H van der Burg, Ellen Kapiteijn, John B A G Haanen, Winan J van Houdt, Els M E Verdegaal, Marij J P Welters, Jessica S W Borgers, Tineke J van Wesemael, Johannes V van Thienen, Kyra A Gelderman, Dirk J A R Moes

    Published 2024-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Metabolic parameters on baseline and early [18F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma

    Metabolic parameters on baseline and early [18F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma by Bernies van der Hiel, Berlinda J. de Wit - van der Veen, Alfons J. M. van den Eertwegh, Wouter V. Vogel, Marcel P. M. Stokkel, Marta Lopez-Yurda, Ronald Boellaard, Ellen W. Kapiteijn, Geke A. P. Hospers, Maureen J. B. Aarts, Filip Y. F. L. de Vos, Marye J. Boers-Sonderen, Astrid A. M. van der Veldt, Jan Willem B. de Groot, John B. A. G. Haanen

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

    Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up by Annelies Jorritsma-Smit, Michel W J M Wouters, Bianca Heemskerk, Nienke van Rooij, Pia Kvistborg, John B A G Haanen, Joost H van den Berg, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Marit M van Buuren, Hergen Spits, Remko Schotte, Henk Mallo, Matthias Karger, Joris A van der Hage, Loes M Pronk, Marnix H Geukes Foppen, Christian U Blank, Jos H Beijnen, Bastiaan Nuijen, Ton N Schumacher

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: